Daiichi Sankyo Co Ltd ADR DSNKY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Merck, Daiichi Sankyo Withdraw Application for Accelerated Approval of Lung Cancer Treatment
-
AstraZeneca, Daiichi Breast-Cancer Drug Gets Nod in England After U.S. Pharma Deal
-
AstraZeneca, Daiichi Sankyo Get New EU Approval for Breast Cancer Drug
-
AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review — Update
-
Breast Cancer Treatment from Daiichi Sankyo, AstraZeneca Approved in U.S.
-
Shares of Japanese Drugmaker Daiichi Sankyo Tumble on Delay in Earnings
-
Daiichi Sankyo to Sell Over-the-Counter Drug Business for $1.55 Billion
-
AstraZeneca, Daiichi Sankyo Drug Gets U.S. Nod for Breast-Cancer Label Expansion
Trading Information
- Previous Close Price
- $17.38
- Day Range
- $16.86–17.48
- 52-Week Range
- $14.98–27.50
- Bid/Ask
- $14.50 / $52.04
- Shares Outstanding
- 1.82B
- Market Cap
- $31.61B
- Volume/Avg
- 100,714 / 126,901
Key Statistics
- Price/Earnings (Normalized)
- 17.87
- Price/Sales
- 2.28
- Dividend Yield (Trailing)
- 2.83%
- Dividend Yield (Forward)
- 2.83%
- Dividend Payment Schedule
- Jun, Dec
- Total Yield
- 6.02%
Company Profile
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 20,171
- Website
- https://www.daiichisankyo.co.jp
Competitors
Valuation
|
Metric
|
DSNKY
|
AZN
|
4519
|
|---|---|---|---|
Price/Earnings (Normalized) | 17.87 | 14.51 | 20.68 |
Price/Book Value | 3.01 | 4.85 | 4.90 |
Price/Sales | 2.28 | 4.06 | 7.39 |
Price/Cash Flow | 36.34 | 16.05 | 18.66 |
Price/Earnings
DSNKY
AZN
4519
Financial Strength
|
Metric
|
DSNKY
|
AZN
|
4519
|
|---|---|---|---|
Quick Ratio | 1.46 | 0.66 | 3.43 |
Current Ratio | 2.42 | 0.89 | 4.35 |
Interest Coverage | 28.88 | 7.99 | 9,780.06 |
Quick Ratio
DSNKY
AZN
4519
Profitability
|
Metric
|
DSNKY
|
AZN
|
4519
|
|---|---|---|---|
Return on Assets (Normalized) | — | 9.00% | 19.65% |
Return on Equity (Normalized) | — | 21.69% | 23.42% |
Return on Invested Capital (Normalized) | — | 14.36% | 23.42% |
Return on Assets
DSNKY
AZN
4519
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|>%c$#d? | LOCK|TW$ | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|!W>>>y& | LOCK|&&n | $617B | |||
| AbbVie Inc
ABBV
| LOCK|R>Wl^X> | LOCK|hH> | $464B | |||
| Merck & Co Inc
MRK
| LOCK|%wrF#d | LOCK|?<K | $356B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|CLffxqZ< | LOCK|>n | $333B | |||
| Novartis AG ADR
NVS
| LOCK|%wbV>t?^ | LOCK|&x | $266B | |||
| AstraZeneca PLC
AZN
| LOCK|!K$sX<%J | LOCK|Bs? | $243B | |||
| Amgen Inc
AMGN
| LOCK|>?GQ#cn | LOCK|?$Q | $218B | |||
| Gilead Sciences Inc
GILD
| LOCK|?&?t>d | LOCK|&^> | $179B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|DZy>&fX | LOCK|H$F | $165B |
United States